secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001372514-23-000070
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharmaceuticals reports Q1 net loss of $1.9M; positive clinical data for KIO-301, KIO-201, KIO-101
--------------------------------------------------------------------------------

- Net loss narrowed to $1.9M from $3.6M in Q1 2022; cash & equivalents $3.4M plus $1.7M R&D tax receivables.
- KIO-301 (ABACUS trial) showed profound light perception improvements in a blind RP patient; full results by end 2023.
- KIO-201 Phase 2 PCED trial met primary endpoint in 5 of 8 patients at 4 weeks; planning registration study.
- KIO-101 Phase 2 OPRA trial first patient enrolled in April; targeting ocular surface disease from autoimmune conditions.
- Approximately $9.6M available under equity line of credit; R&D expenses fell to $0.4M from $0.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000070/0001372514-23-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000070/kprx-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001372514-23-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer